000177326 001__ 177326
000177326 005__ 20240229133737.0
000177326 0247_ $$2doi$$a10.3389/fonc.2021.753768
000177326 0247_ $$2pmid$$apmid:34737961
000177326 0247_ $$2pmc$$apmc:PMC8562722
000177326 0247_ $$2altmetric$$aaltmetric:115463938
000177326 037__ $$aDKFZ-2021-02438
000177326 041__ $$aEnglish
000177326 082__ $$a610
000177326 1001_ $$0P:(DE-He78)a9a6232a4fccf84da58752c9cc24be23$$aBostel, Tilmann$$b0$$udkfz
000177326 245__ $$aComparative Analyses of Two Established Scores to Assess the Stability of Spinal Bone Metastases Before and After Palliative Radiotherapy.
000177326 260__ $$aLausanne$$bFrontiers Media$$c2021
000177326 3367_ $$2DRIVER$$aarticle
000177326 3367_ $$2DataCite$$aOutput Types/Journal article
000177326 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1636371717_31062
000177326 3367_ $$2BibTeX$$aARTICLE
000177326 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000177326 3367_ $$00$$2EndNote$$aJournal Article
000177326 500__ $$a#LA:E055#
000177326 520__ $$aTo compare two validated spinal instability scores regarding the stabilizing effects and skeletal-related events (SREs) of palliative radiotherapy (RT) in patients with spinal bone metastases (SBM).Two hundred eighty-two osteolytic SBM of lung or breast cancer patients were analyzed for stability before and following RT based on the Spinal Instability Neoplastic Score (SINS) or the Taneichi score. Score concordance was quantified by absolute agreement and Cohen's kappa coefficient. SREs were defined as fractures or local progression after RT. OS was quantified as the time between the start of RT and death from any cause.At 3 and 6 months after RT, 35 and 50% of initially unstable SBM were re-stabilized according to SINS in patients still alive. Corresponding Taneichi score-based stabilization proportions were 25 and 46%, respectively. Comparison of both stability scores showed high absolute agreement for all time-points (range 71-78%, kappa range 0.35-0.44). SRE occurred more frequently in initially unstable SBM compared to stable SBM according to SINS (14 vs. 5%), but no such association could be shown for the Taneichi-based instability criterion. Poor general condition of patients was negatively associated with SINS-measured re-stabilization after 6 months, but no predictive factor for re-stabilization could be found for the Taneichi score.Despite the relatively high agreement between both stabilization scores, the SINS should be considered the standard for future studies on the stabilization effects of RT in SBM.
000177326 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000177326 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000177326 650_7 $$2Other$$aSINS
000177326 650_7 $$2Other$$ainstability
000177326 650_7 $$2Other$$aradiotherapy
000177326 650_7 $$2Other$$askeletal-related events
000177326 650_7 $$2Other$$aspinal bone metastases
000177326 7001_ $$0P:(DE-HGF)0$$aAkbaba, Sati$$b1
000177326 7001_ $$aWollschläger, Daniel$$b2
000177326 7001_ $$0P:(DE-HGF)0$$aKlodt, Tristan$$b3
000177326 7001_ $$0P:(DE-HGF)0$$aOebel, Laura$$b4
000177326 7001_ $$0P:(DE-HGF)0$$aMayer, Arnulf$$b5
000177326 7001_ $$0P:(DE-HGF)0$$aDrabke, Sophia$$b6
000177326 7001_ $$0P:(DE-HGF)0$$aSprave, Tanja$$b7
000177326 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b8$$udkfz
000177326 7001_ $$aFörster, Robert$$b9
000177326 7001_ $$aRief, Harald$$b10
000177326 7001_ $$0P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9$$aRühle, Alexander$$b11$$udkfz
000177326 7001_ $$0P:(DE-HGF)0$$aGrosu, Anca-Ligia$$b12
000177326 7001_ $$0P:(DE-HGF)0$$aSchmidberger, Heinz$$b13
000177326 7001_ $$0P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd$$aNicolay, Nils$$b14$$eLast author$$udkfz
000177326 773__ $$0PERI:(DE-600)2649216-7$$a10.3389/fonc.2021.753768$$gVol. 11, p. 753768$$p753768$$tFrontiers in oncology$$v11$$x2234-943X$$y2021
000177326 909CO $$ooai:inrepo02.dkfz.de:177326$$pVDB
000177326 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a9a6232a4fccf84da58752c9cc24be23$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000177326 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000177326 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000177326 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000177326 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000177326 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000177326 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000177326 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000177326 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)80e100a16534f5fc67f7436ee67a47f9$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000177326 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000177326 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000177326 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8d52e7ff1ccaac7dbf0232fdcb0168bd$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000177326 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000177326 9141_ $$y2021
000177326 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT ONCOL : 2019$$d2021-01-27
000177326 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-27
000177326 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-27
000177326 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-01-27
000177326 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-01-27
000177326 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-01-27
000177326 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-01-27
000177326 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-01-27
000177326 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-27
000177326 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-27
000177326 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-27
000177326 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-27
000177326 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-27
000177326 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-01-27
000177326 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-27
000177326 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-01-27
000177326 9201_ $$0I:(DE-He78)FM01-20160331$$kFM01$$lDKTK FM zentral$$x0
000177326 9201_ $$0I:(DE-He78)FR01-20160331$$kFR01$$lDKTK FR zentral$$x1
000177326 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000177326 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x3
000177326 9201_ $$0I:(DE-He78)E055-20160331$$kE055$$lE055 KKE Translationale Radioonkologie$$x4
000177326 980__ $$ajournal
000177326 980__ $$aVDB
000177326 980__ $$aI:(DE-He78)FM01-20160331
000177326 980__ $$aI:(DE-He78)FR01-20160331
000177326 980__ $$aI:(DE-He78)HD01-20160331
000177326 980__ $$aI:(DE-He78)E050-20160331
000177326 980__ $$aI:(DE-He78)E055-20160331
000177326 980__ $$aUNRESTRICTED